<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167881</url>
  </required_header>
  <id_info>
    <org_study_id>1245.28</org_study_id>
    <secondary_id>2009-016244-39</secondary_id>
    <nct_id>NCT01167881</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for
      BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2
      diabetes mellitus and insufficient glycaemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.</measure>
    <time_frame>Baseline and 104 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change in Body Weight From Baseline After 104 Weeks of Treatment.</measure>
    <time_frame>baseline and 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.</measure>
    <time_frame>baseline and 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment.</measure>
    <time_frame>baseline and 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment.</measure>
    <time_frame>baseline and 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline in HbA1c After 52 Weeks of Treatment.</measure>
    <time_frame>baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Body Weight From Baseline After 52 Weeks of Treatment.</measure>
    <time_frame>baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.</measure>
    <time_frame>baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment.</measure>
    <time_frame>baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.</measure>
    <time_frame>baseline and 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1549</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 dose plus metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride 1-4 mg plus metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Medium dose once daily</description>
    <arm_group_label>BI 10773 dose plus metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>1-4 mg once daily</description>
    <arm_group_label>Glimepiride 1-4 mg plus metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773</description>
    <arm_group_label>Glimepiride 1-4 mg plus metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching Glimepiride</description>
    <arm_group_label>BI 10773 dose plus metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis typ 2 diabetes mellitus

          -  Male and female on diet and exercise regimen, pre-treated with metformin 12 weeks
             prior to randomisation

          -  HbA1c equal or greater than 7.0% and less than or equal to 10% at visit 1

          -  18 years or more

          -  BMI equal or less than 45Kg/m2

        Exclusion criteria:

          -  Uncontrolled hyperglycemia defined as glucose more that 13.3 mmol/L after overnight
             fast during placebo run-in

          -  Any other antidiabetic drug within 12 weeks prior to randomisation except metformin

          -  Acute coronary syndrome (non-STEMI, STEMI unstable angina pectoris), stroke or
             transient ischemic attack within 12 weeks of informed consent

          -  Indication of liver disease

          -  Moderate to severe renal impairment

          -  Bariatric surgery within past 2 years

          -  Medical history of cancer or treatment for cancer within last 5 years

          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell

          -  Contraindications hypersensitivity to concomitant drugs

          -  Treatment with anti-obesity drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.28.10005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradednton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.10013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.54010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Langley</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grand Falls-Windsor</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Collingwood</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stayner</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strathroy</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.20076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.57007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.57005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.57003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.57006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mlada Boleslav</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.42008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 1</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.42006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.72001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.72004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.72003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.72002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.85201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.85207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.85202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91213 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91211 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91212 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.91209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uttar Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.39021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.39022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chieri (to)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.39016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucca</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.39018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.39019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.39017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monserrato (ca)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.39023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.39020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.60003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.60006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.60005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.60009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.60004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pahang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.60007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perak</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.60010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pulau Pinang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selangor Darul Ehsan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.52006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.52008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cuautla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.52009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.52007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>'s HERTOGENBOSCH</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.31020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Losser</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hønefoss</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandefjord</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cavite City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaro Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacloban</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.63014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tagbilaran City, Bohol</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.35006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.35002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.35012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.35016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boksburg North</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bryanston</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia South</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.76014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burjasot</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pineda de Mar</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarrega - Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.46009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.46008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.41015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ascona</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.41017 Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.88004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.88003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.88005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan Hsien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.88002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei Hsien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.88001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.66006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.66007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.66004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muang District</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.66008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nakhonratchasima</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Addlestone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ashford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Balham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barnstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burbage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chestfield, Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Doncaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ely</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Midsomer Norton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.28.44017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <results_first_submitted>July 17, 2014</results_first_submitted>
  <results_first_submitted_qc>July 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2014</results_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>An optional 2-year extension was implemented in this trial through a protocol amendment, which brought the total length of treatment to 4 years. However, some sites did not participate in the 2-year extension, and so considered patients to have completed treatment after 2 years.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Empaglifozin 25 mg</title>
          <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
        </group>
        <group group_id="P2">
          <title>Glimepiride</title>
          <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="769"/>
                <participants group_id="P2" count="780"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed After 2 Years Treatment</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed After 4 Years Treatment</title>
              <participants_list>
                <participants group_id="P1" count="515"/>
                <participants group_id="P2" count="462"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="610"/>
                <participants group_id="P2" count="589"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refusal to cont., not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other not defined above</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS), All patients randomised, treated with at least one dose of study drug, and with a baseline HbA1c value.</population>
      <group_list>
        <group group_id="B1">
          <title>Empaglifozin 25 mg</title>
          <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
        </group>
        <group group_id="B2">
          <title>Glimepiride</title>
          <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="765"/>
            <count group_id="B2" value="780"/>
            <count group_id="B3" value="1545"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="10.3"/>
                    <measurement group_id="B2" value="55.7" spread="10.4"/>
                    <measurement group_id="B3" value="55.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                    <measurement group_id="B2" value="359"/>
                    <measurement group_id="B3" value="692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="432"/>
                    <measurement group_id="B2" value="421"/>
                    <measurement group_id="B3" value="853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Body Weight From Baseline After 104 Weeks of Treatment.</title>
        <time_frame>baseline and 104 weeks</time_frame>
        <population>FAS (LOCF) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Body Weight From Baseline After 104 Weeks of Treatment.</title>
          <population>FAS (LOCF) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.11" spread="0.13"/>
                    <measurement group_id="O2" value="1.33" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for main analysis (104 weeks):
Non-inferiority in HbA1c change from baseline at 104 weeks,
Superiority in body weight change from baseline at 104 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 104 weeks,
Superiority in HbA1c change from baseline at 104 weeks,
Superiority in systolic blood pressure change from baseline at 104 weeks,
Superiority in diastolic blood pressure change from baseline at 104 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline weight, baseline HbA1c as linear covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.87</ci_lower_limit>
            <ci_upper_limit>-4.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.</title>
        <time_frame>Baseline and 104 weeks</time_frame>
        <population>FAS (LOCF) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment.</title>
          <population>FAS (LOCF) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.03"/>
                    <measurement group_id="O2" value="-0.55" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for main analysis (104 weeks):
Non-inferiority in HbA1c change from baseline at 104 weeks,
Superiority in body weight change from baseline at 104 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 104 weeks,
Superiority in HbA1c change from baseline at 104 weeks,
Superiority in systolic blood pressure change from baseline at 104 weeks,
Superiority in diastolic blood pressure change from baseline at 104 weeks.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was tested through a two-sided 97.5% confidence interval for the treatment effect of empagliflozin minus the effect of glimepiride in change from baseline in HbA1c. The null-hypothesis of material inferiority of empagliflozin was rejected if the confidence interval is entirely below the non-inferiority margin 0.3%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline HbA1c as linear covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for main analysis (104 weeks):
Non-inferiority in HbA1c change from baseline at 104 weeks,
Superiority in body weight change from baseline at 104 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 104 weeks,
Superiority in HbA1c change from baseline at 104 weeks,
Superiority in systolic blood pressure change from baseline at 104 weeks,
Superiority in diastolic blood pressure change from baseline at 104 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0153</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline HbA1c as linear covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.</title>
        <time_frame>baseline and 104 weeks</time_frame>
        <population>Treated set, all patients treated with at least one dose of randomised study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment.</title>
          <population>Treated set, all patients treated with at least one dose of randomised study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for main analysis (104 weeks):
Non-inferiority in HbA1c change from baseline at 104 weeks,
Superiority in body weight change from baseline at 104 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 104 weeks,
Superiority in HbA1c change from baseline at 104 weeks,
Superiority in systolic blood pressure change from baseline at 104 weeks,
Superiority in diastolic blood pressure change from baseline at 104 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusting for baseline HbA1c (&lt;8.5 / &gt;=8.5).</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.102</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.060</ci_lower_limit>
            <ci_upper_limit>0.173</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment.</title>
        <time_frame>baseline and 104 weeks</time_frame>
        <population>FAS (LOCF-H) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Systolic Blood Pressure (SBP) From Baseline After 104 Weeks of Treatment.</title>
          <population>FAS (LOCF-H) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="0.5"/>
                    <measurement group_id="O2" value="2.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for main analysis (104 weeks):
Non-inferiority in HbA1c change from baseline at 104 weeks,
Superiority in body weight change from baseline at 104 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 104 weeks,
Superiority in HbA1c change from baseline at 104 weeks,
Superiority in systolic blood pressure change from baseline at 104 weeks,
Superiority in diastolic blood pressure change from baseline at 104 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline SBP, baseline HbA1c as linear covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.0</ci_lower_limit>
            <ci_upper_limit>-4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment.</title>
        <time_frame>baseline and 104 weeks</time_frame>
        <population>FAS (LOCF-H) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Diastolic Blood Pressure (DBP) From Baseline After 104 Weeks of Treatment.</title>
          <population>FAS (LOCF-H) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.3"/>
                    <measurement group_id="O2" value="0.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for main analysis (104 weeks):
Non-inferiority in HbA1c change from baseline at 104 weeks,
Superiority in body weight change from baseline at 104 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 104 weeks,
Superiority in HbA1c change from baseline at 104 weeks,
Superiority in systolic blood pressure change from baseline at 104 weeks,
Superiority in diastolic blood pressure change from baseline at 104 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline DBP, baseline HbA1c as linear covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>-1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline in HbA1c After 52 Weeks of Treatment.</title>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>FAS (LOCF) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline in HbA1c After 52 Weeks of Treatment.</title>
          <population>FAS (LOCF) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.03"/>
                    <measurement group_id="O2" value="-0.66" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for first interim analysis (52 weeks):
Non-inferiority in HbA1c change from baseline at 52 weeks,
Superiority in body weight change from baseline at 52 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 52 weeks,
Superiority in systolic blood pressure change from baseline at 52 weeks,
Superiority in diastolic blood pressure change from baseline at 52 weeks.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was tested through a two-sided 97.5% confidence interval for the treatment effect of empagliflozin minus the effect of glimepiride in change from baseline in HbA1c. The null-hypothesis of material inferiority of empagliflozin was rejected if the confidence interval is entirely below the non-inferiority margin 0.3%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline HbA1c as linear covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Body Weight From Baseline After 52 Weeks of Treatment.</title>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>FAS (LOCF) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Body Weight From Baseline After 52 Weeks of Treatment.</title>
          <population>FAS (LOCF) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.21" spread="0.12"/>
                    <measurement group_id="O2" value="1.59" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for first interim analysis (52 weeks):
Non-inferiority in HbA1c change from baseline at 52 weeks,
Superiority in body weight change from baseline at 52 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 52 weeks,
Superiority in systolic blood pressure change from baseline at 52 weeks,
Superiority in diastolic blood pressure change from baseline at 52 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline weight, baseline HbA1c as linear covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.16</ci_lower_limit>
            <ci_upper_limit>-4.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.</title>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>Treated set, all patients treated with at least one dose of randomised study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment.</title>
          <population>Treated set, all patients treated with at least one dose of randomised study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for first interim analysis (52 weeks):
Non-inferiority in HbA1c change from baseline at 52 weeks,
Superiority in body weight change from baseline at 52 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 52 weeks,
Superiority in systolic blood pressure change from baseline at 52 weeks,
Superiority in diastolic blood pressure change from baseline at 52 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test adjusting for baseline HbA1c (&lt;8.5 / &gt;=8.5).</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.077</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment.</title>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>FAS (LOCF-H) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Systolic Blood Pressure (SBP) From Baseline After 52 Weeks of Treatment.</title>
          <population>FAS (LOCF-H) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="0.5"/>
                    <measurement group_id="O2" value="2.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for first interim analysis (52 weeks):
Non-inferiority in HbA1c change from baseline at 52 weeks,
Superiority in body weight change from baseline at 52 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 52 weeks,
Superiority in systolic blood pressure change from baseline at 52 weeks,
Superiority in diastolic blood pressure change from baseline at 52 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline SBP, baseline HbA1c as linear covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>-4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.</title>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>FAS (LOCF-H) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Empaglifozin 25 mg</title>
            <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily.
Empagliflozin: 25 mg once daily
Placebo: Placebo matching Glimepiride</description>
          </group>
          <group group_id="O2">
            <title>Glimepiride</title>
            <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily.
Glimepiride: 1-4 mg once daily
Placebo: Placebo matching Empagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Diastolic Blood Pressure (DBP) From Baseline After 52 Weeks of Treatment.</title>
          <population>FAS (LOCF-H) – Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF); Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.3"/>
                    <measurement group_id="O2" value="1.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Testing Hierarchy for first interim analysis (52 weeks):
Non-inferiority in HbA1c change from baseline at 52 weeks,
Superiority in body weight change from baseline at 52 weeks,
Superiority in occurrence of confirmed hypoglycaemic adverse events at 52 weeks,
Superiority in systolic blood pressure change from baseline at 52 weeks,
Superiority in diastolic blood pressure change from baseline at 52 weeks.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The superiority tests performed at 104 weeks and the superiority tests performed at 52 weeks both used a nominal significance level of 2.5% to maintain the overall significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment, geographical region, renal function at baseline as fixed effects and baseline DBP, baseline HbA1c as linear covariates.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 years.</time_frame>
      <desc>All adverse events (AE), serious and non-serious, occurring during the course of the clinical trial were collected, documented, and reported to the sponsor by the investigator on the appropriate case report form (CRF) or serious adverse event (SAE) reporting forms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Empa 25mg</title>
          <description>Patients received one Empagliflozin 25 mg tablet and one placebo Glimepiride capsule orally once daily. Empagliflozin: 25 mg once daily Placebo: Placebo matching Glimepiride</description>
        </group>
        <group group_id="E2">
          <title>Glimepiride</title>
          <description>Patients received one Glimepiride capsule and one placebo Empagliflozin tablet orally once daily. Glimepiride: 1-4 mg once daily Placebo: Placebo matching Empagliflozin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Ventricle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pituitary-dependent Cushing's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Endocrine ophthalmopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Retinal neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Anorectal varices</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Anorectal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Proctitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cystitis escherichia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Post procedural constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Melanoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Metastatic ocular melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Nasal neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Paranasal sinus benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Delusional disorder, unspecified type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Omentectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Oophorectomy bilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="580" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="637" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="228" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="780"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="765"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="780"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It should be noted that not all patients were followed up for 4 years with regard to the frequencies of adverse events presented up to 4 years.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

